ACT_597355/2023

METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

VerletzungHauptverletzungsklageDusseldorf LDInfringement Action—

Dieser Fall zitiert

In den Entscheidungen dieses Falls zitierte Quellen.

Quelle	Rechtsfrage	Bindungskraft	Auszug
54(4)	novelty of second medical use – substance used for specific use not in prior art	Bindend	a substance or composition within the meaning of Art. 54(4) EPC is used for any specific use which is not comprised in the state of the art.
54(5)	notional novelty afforded to second medical use claims	Bindend	In order to benefit from the notional novelty afforded by Art. 54(5) EPC, second medical use claims must relate to a specific use in a method according to Art. 53(c) EPC.
53(c)	second medical use claims – method of treatment	Bindend	second medical use claims must relate to a specific use in a method according to Art. 53(c) EPC.
73(1)	right to appeal within two months	Bindend	An appeal against this decision may be brought before the Court of Appeal by any party whose claims have been unsuccessful, in whole or in part, within two months of service of the decision (Art. 73(1) UPCA, R. 220.1 (a) RoP, 224.1 (a) RoP).
69.4	security for costs	Hintergrund	An authentic copy of the enforceable order will be issued by the Deputy-Registrar upon request of the enforcing party, R. 69 RegR.
82	enforcement of orders	Bindend	INFORMATION ON ENFORCEMENT (Art. 82 UPCA, Art. 37(2) UPCS, R. 118.8, 158.2, 354, 355.4 RoP)

Quelle	Rechtsfrage	Bindungskraft	Auszug
220.1	time limit for appeal	Bindend	An appeal against this decision may be brought before the Court of Appeal by any party whose claims have been unsuccessful, in whole or in part, within two months of service of the decision (Art. 73(1) UPCA, R. 220.1 (a) RoP, 224.1 (a) RoP).

Zitiert in

Spätere UPC-Entscheidungen, die diesen Fall zitieren.

Bisher in keiner anderen Entscheidung unseres Korpus zitiert.